Behavioral and Developmental Neuropsychiatry (BDNP) Preclinical Research

Our BDNP Preclinical Research focuses on developing new targeted drug treatments in developmental disabilities. We utilize mouse models of Fragile X Syndrome, Angelman Syndrome, and autism spectrum disorders to identify novel targets. The lab tests the effectiveness of new compounds and repurposed drugs for the treatment of behavior, molecular, and cellular abnormalities associated with these disorders.

We are also developing novel biomarkers of disease pathophysiology and treatment response that will hopefully lead to more personalized treatment approaches and successful outcomes for children and adults with developmental disabilities.

Related Publications

Show All

Dominick K, Wink LK, McDougle CJ, Erickson CA. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2015 Jun;25(5):397-401.

Adler BA, Wink LK, Early M, Shaffer R, Minshawi N, McDougle CJ, Erickson CA. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study. Autism. 2015 Jan;19(1):102-6.

Erickson CA, Ray B, Maloney B, Wink LK, Bowers K, Schaefer TL, McDougle CJ, Sokol DK, Lahiri DK. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res. 2014 Dec;59:220-8.

Wink LK, O'Melia AM, Shaffer RC, Pedapati E, Friedmann K, Schaefer T, Erickson CA. Intranasal ketamine treatment in an adult with autism spectrum disorder. J Clin Psychiatry. 2014 Aug;75(8):835-6.

Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014 Apr;44(4):958-64.

Erickson CA, Wink LK, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, McDougle CJ. Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. J Autism Dev Disord. 2014 Apr;44(4):981-7.

Wink LK, Early M, Schaefer T, Pottenger A, Horn P, McDougle CJ, Erickson CA. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol. 2014 Mar;24(2):78-82.

Additional Publications

For a complete and updated list of publications from the Erickson-Wink Lab please view this PubMed listing.

Contact Us

Tori Schaefer, PhD
Division of Psychiatry
3430 Burnet Ave. MLC 4002
Cincinnati, OH 45229

Phone: 513-803-3740

Funding Support BDNP Preclinical Research